Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $55.30 Average PT from Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $55.30.

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday. The Goldman Sachs Group lowered their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. Morgan Stanley started coverage on Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price objective for the company. Finally, UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLDX. Vanguard Group Inc. increased its holdings in shares of Celldex Therapeutics by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock valued at $98,098,000 after purchasing an additional 12,213 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after purchasing an additional 676,771 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after purchasing an additional 847,264 shares in the last quarter. Deep Track Capital LP purchased a new position in shares of Celldex Therapeutics in the fourth quarter valued at $38,919,000. Finally, Rock Springs Capital Management LP increased its position in shares of Celldex Therapeutics by 10.7% in the fourth quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock valued at $30,885,000 after buying an additional 118,404 shares in the last quarter.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock traded up $0.51 during trading on Friday, reaching $18.91. 707,745 shares of the company were exchanged, compared to its average volume of 885,101. The stock's 50 day simple moving average is $19.02 and its two-hundred day simple moving average is $23.01. The company has a market capitalization of $1.26 billion, a P/E ratio of -7.36 and a beta of 1.39. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, equities analysts forecast that Celldex Therapeutics will post -2.48 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.